Quantcast
Last updated on April 16, 2014 at 16:55 EDT

Latest G protein Stories

Heart Attack Patients May Soon Have Side Effect-Free Drug Option
2014-03-12 06:36:52

April Flowers for redOrbit.com - Your Universe Online A new drug designed to stop a heart attack in its tracks, while reducing the damage caused, all without side effects, is one step closer to development thanks to a group of Melbourne scientists from Monash University. New hope for thousands of people who experience heart attacks and heart failure is provided by the study, published in a recent issue of Proceedings of the National Academy of Sciences. A team of scientists, led by...

Detailed Picture Of Protein Linked To Learning, Pain And Brain Disorders Created By Scientists
2014-03-07 11:26:29

Scripps Research Institute Researchers at The Scripps Research Institute (TSRI) and Vanderbilt University have created the most detailed 3-D picture yet of a membrane protein that is linked to learning, memory, anxiety, pain and brain disorders such as schizophrenia, Parkinson's, Alzheimer's and autism. "This receptor family is an exciting new target for future medicines for treatment of brain disorders," said P. Jeffrey Conn, PhD, Lee E. Limbird Professor of Pharmacology and director...

2013-12-18 08:28:28

STRASBOURG AND MONTRÉAL, Dec. 18, 2013 /PRNewswire/ - Domain Therapeutics, a France-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G-protein coupled receptors (GPCRs), is pleased to announce the signing of a licensing and partnership agreement on GPCR biosensor technology with Université de Montréal (UdeM) and its commercialization unit, with the Institute for Research in Immunology and Cancer -...

2013-10-03 08:29:30

-- Brings Omeros' Total to 52 Class A Orphans and Opens Way to New Oral Drugs to Treat Diabetes and Osteoporosis -- SEATTLE, Oct. 3, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of six additional orphan G protein-coupled receptors (GPCRs) that have been linked to a wide range of diseases in the areas of neurologic disorders, cardiovascular disease and oncology. Identification of...

2013-07-22 04:20:43

WELWYN GARDEN CITY, England and BOSTON, July 22, 2013 /PRNewswire/ -- StaR(R) Generated to Important GPCR Target Selected by Cubist Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved the first research milestone in its collaboration with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), which was announced in January 2013. The milestone is based on the generation of a stabilised (StaR(R)) form of a GPCR...

2013-07-17 12:26:28

WELWYN GARDEN CITY, England and BOSTON, July 17, 2013 /PRNewswire/ -- Unique structural insights from CRF1 structure will drive drug discovery programmes targeting important Class B GPCRs including GLP1 (diabetes) Heptares Therapeutics, the leading GPCR drug discovery and development company, announces the publication of a scientific article describing the high resolution X-ray crystal structure of the corticotropin-releasing factor receptor 1 (CRF1)...

2013-07-16 15:42:18

Brandeis scientists bring us a step closer to understanding how to control cancer cells without harming healthy ones The nasty side effects of radiation and chemotherapy are well known: fatigue, hair loss and nausea, to name a few. Cancer treatment can seem as harsh as the disease because it can't differentiate healthy cells from cancerous cells, killing both. But what if there were a way to control or stop the growth of cancer cells without harming other cells? Brandeis biologist...

2013-04-22 22:29:32

A three-dimensional image of one of the proteins that serves as an on-off switch as it binds to receptors on the surface of a cell suggests there may be a sort of main power switch that could be tripped. These surface receptors are responsible for helping cells discern light, set the heart racing, or detect pain. The finding, published online April 21, 2013, in the journal Nature by a research collaboration involving this year's Nobel laureates in chemistry, could help in the development...

2013-01-16 08:28:55

SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its proprietary Cellular Redistribution Assay (CRA) technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G Protein-Coupled Receptors (GPCRs) for drug development, has identified small molecules that interact with a Class B GPCR. Like the Class A GPCRs, Class B receptors are important players in a broad range of disorders, having been linked to various types of...

2013-01-07 08:28:42

WELWYN GARDEN CITY, England and BOSTON, January 7, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced they have signed an agreement with Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases. Under the terms of the...